HIV research
Human immunodeficiency virus (HIV) – the etiologic agent of AIDS – is one of the most intensively studied disease organisms in history. Since its first identification in the early 1980s, HIV has transformed into a pandemic, globally infecting more 36 million people and annually contributing to the deaths of hundreds of thousands of patients – particularly in low income countries. This Milestone charts the history of HIV research on an interactive Timeline, from its origins to the latest developments in HIV treatment, vaccines and insights from the study of HIV/AIDS pathogenesis.
-
Funded by a grant from:
-
Produced with support from:
-
Produced with support from:
This Milestone is editorially independent, produced with financial support from a third party. About this content.
Nature Research is pleased to acknowledge funding provided by a grant from Merck & Co., Inc. in Kenilworth, New Jersey, as well as the financial support of Gilead, and Janssen Pharmaceutical Companies of Johnson & Johnson in producing this Nature Milestone. The sponsor retains sole responsibility for the following messages.
Produced with grant support from Merck & Co., Inc. in Kenilworth, New Jersey.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we have ambitious goals. We strive to discover and develop novel therapeutics and vaccines to prevent, treat and cure infectious diseases worldwide, improving treatment outcomes and patients’ lives.
We have a legacy in HIV that spans over 25 years and in partnership with others have introduced eight approved HIV medicines over the past decade. Our HIV medicines have helped transform the efficacy and tolerability of treatment in simplified formulations.
Through our extensive research and development programs and vital collaborations, we continue to change the course of HIV. Together with our global partners, we have initiated the first efficacy study for a “mosaic”-based investigational HIV-1 preventive vaccine. We’re also working to develop the first long-acting injectable regimen of HIV medication, which could offer people living with HIV the option to have monthly injections rather than taking daily treatment.
We work in many ways, but the aim behind all of them is simple: to Make HIV History and change the trajectory of health for humanity.
